Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of C213 (Zolmitriptan Microneedle System) for Acute Cluster Headache
NCT04066023Phase 3Completed
- Sponsor
- Zosano Pharma
- Start
- Oct 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zolmitriptan in Cluster Headache (CH) (3 arms), sponsored by Zosano Pharma. Primary endpoints: Percentage of Subjects Who Achieve Pain Relief and Percentage of Subjects Who Achieve Sustained Pain Relief. Started Oct 2019; status: completed.
02
Drugs
zolmitriptan
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NCT04066023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066023.